Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki

Bringing the first agent to market for the indication, on August 5, 2022, the U.S. Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-low breast cancer based on results from the DESTINY-Breast04 trial that demonstrated improved progression-free and overall survival. FDA also gave fam-trastuzumab deruxtecan its fourth approval on August 11, 2022, for unresectable or metastatic HER2-activating non-small cell lung cancer.